Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYP19A1 | P11511 | 13/20 | 0.58 |
| ▸ | ACHE | P22303 | 1/20 | 0.46 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.41 |
| ▸ | NOTUM | Q6P988 | 1/20 | 0.40 |
| ▸ | RELA | Q04206 | 1/20 | 0.39 |
| ▸ | MAPT | P10636 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL16057361 | 0.74 | CYP19A1 (0.47) | CYP19A1ALDH1A1NOTUM | |
| SCHEMBL9965135 | 0.73 | CYP19A1 (0.70) | CYP19A1ALDH1A1NOTUMMAPT | |
| SCHEMBL9945330 | 0.72 | CYP19A1 (1.00) | CYP19A1NOTUM | |
| SCHEMBL9945323 | 0.72 | CYP19A1 (0.68) | CYP19A1NOTUM | |
| SCHEMBL5865736 | 0.71 | CYP19A1 (1.00) | CYP19A1ALDH1A1MAPT | |
| SCHEMBL11965157 | 0.69 | ACHE (0.65) | CYP19A1ACHEALDH1A1RELAMAPT | |
| SCHEMBL9136047 | 0.69 | CYP19A1 (0.42) | CYP19A1ACHEALDH1A1NOTUMMAPT | |
| SCHEMBL9895460 | 0.69 | CYP2C9 (0.50) | NOTUMMAPT | |
| SCHEMBL6347435 | 0.68 | ACHE (0.71) | CYP19A1ACHEALDH1A1RELAMAPT | |
| SCHEMBL16865571 | 0.68 | ACHE (0.71) | CYP19A1ACHEALDH1A1RELAMAPT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8669274-B2 | Metalloenzyme inhibitor compounds | VIAMET PHARMACEUTICALS, INC. (US) | 2014-03-11 | — | — | US | disclosed |
| US-8669274-B2 | Metalloenzyme inhibitor compounds | VIAMET PHARMACEUTICALS, INC. (US) | 2014-03-11 | — | — | US | disclosed |
| US-20120149729-A1 | METALLOENZYME INHIBITOR COMPOUNDS | VIAMET PHARMACEUTICALS, INC. (US) | 2012-06-14 | — | — | US | disclosed |
| US-20120149729-A1 | METALLOENZYME INHIBITOR COMPOUNDS | VIAMET PHARMACEUTICALS, INC. (US) | 2012-06-14 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120149729-A1 | METALLOENZYME INHIBITOR COMPOUNDS | MMEL1, GPX1, MPO | CYP19A1 898/4885ACHE 101/4885ALDH1A1 289/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.